Key Points
- MoonLake Immunotherapeutics CEO Da Silva Jorge Santos sold 47,775 shares on July 1 at an average price of $20.03, worth about $956,933. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still directly owns 2.88 million shares.
- The CEO has been active in selling stock recently, including two earlier transactions in April totaling more than 150,000 shares and about $2.75 million combined.
- MLTX remains a volatile biotech name: the stock opened at $18.95, the company reported a wider-than-expected quarterly loss, and analysts currently have a consensus rating of Hold with an average price target of $24.21.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 47,775 shares of the business's stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $20.03, for a total transaction of $956,933.25. Following the sale, the chief executive officer directly owned 2,877,118 shares of the company's stock, valued at approximately $57,628,673.54. The trade was a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Da Silva Jorge Santos also recently made the following trade(s):
- On Monday, April 13th, Da Silva Jorge Santos sold 51,873 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $18.23, for a total transaction of $945,644.79.
- On Friday, April 10th, Da Silva Jorge Santos sold 98,127 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $18.41, for a total transaction of $1,806,518.07.
MoonLake Immunotherapeutics Stock Performance
Shares of MLTX opened at $18.95 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 8.60 and a current ratio of 8.60. The stock has a 50 day moving average price of $18.29 and a two-hundred day moving average price of $17.03. The firm has a market capitalization of $1.39 billion, a P/E ratio of -4.90 and a beta of 1.04. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.07). Equities analysts forecast that MoonLake Immunotherapeutics will post -3.71 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Kestra Advisory Services LLC purchased a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter valued at $26,000. EverSource Wealth Advisors LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 221.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company's stock worth $53,000 after buying an additional 1,974 shares during the last quarter. Russell Investments Group Ltd. grew its position in MoonLake Immunotherapeutics by 45.4% during the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company's stock valued at $45,000 after buying an additional 1,069 shares during the period. T. Rowe Price Investment Management Inc. bought a new position in MoonLake Immunotherapeutics during the fourth quarter valued at about $47,000. Finally, FNY Investment Advisers LLC purchased a new stake in MoonLake Immunotherapeutics during the third quarter worth about $28,000. Institutional investors own 93.85% of the company's stock.
Wall Street Analysts Forecast Growth
MLTX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price objective on shares of MoonLake Immunotherapeutics in a report on Monday, June 8th. Rothschild & Co Redburn upgraded shares of MoonLake Immunotherapeutics from a "neutral" rating to a "buy" rating and increased their target price for the company from $12.00 to $40.00 in a report on Thursday, March 19th. Needham & Company LLC raised their price target on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, May 12th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from an "underperform" rating to an "outperform" rating and boosted their price target for the stock from $12.00 to $24.00 in a report on Monday, March 23rd. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 12th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of "Hold" and an average target price of $24.21.
Get Our Latest Research Report on MoonLake Immunotherapeutics
MoonLake Immunotherapeutics Company Profile
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
